A significant study from the University of Cincinnati Cancer Center might just pave the way to more effective pancreatic cancer treatments. Researchers there have discovered how pancreatic cancer cells are holding the line against current treatment regimens. In their research, published in Cancer Research, they've begun to decipher why these cells are notoriously resistant to KRAS inhibitor treatments.
According to the study findings, the KRAS gene, which is altered in over 90% of pancreatic cancer cases, is a significant stumbling block. "We sought to identify critical cellular targets that could improve a pancreatic tumor’s sensitivity to KRAS inhibitors," Dr. Szu-Aun Long, a researcher at the Waters lab, told the University of Cincinnati communications team. The study made use of CRISPR technology to sift through genes and detect which ones affect sensitivity to drugs meant to inhibit KRAS.
Lead researchers, including Andrew Waters, PhD, and co-first authors Haley Todd and Grace Goodheart, were part of the team focusing on EGFR, a protein that promotes cell growth. They found it to be a factor in the cancer cells' resistance to treatments targeting KRAS. In layperson's terms, the study suggests that blocking EGFR in conjunction with KRAS could potentially offer a more robust combat strategy against pancreatic cancer.
While the journey to finding a fail-safe treatment for pancreatic cancer is rife with challenges, Waters remains optimistic. "We have identified certain patient populations that may preferentially respond to anti-KRAS and anti-EGFR combination therapies," he stated in a research announcement, according to UC News. The research is an important piece in the ongoing puzzle of understanding and eventually overcoming pancreatic cancer's persistent resistance to treatment. Goodheart added, "Understanding how cells are resilient and adapt leads us one step closer to being able to provide more efficacious and personalized treatments for patients."
This research is a step toward hope for the more than 60,000 people in the United States who are diagnosed with pancreatic cancer each year. With scientific endeavors such as these shedding light on the intricacies of cancer treatment resistance, a future where pancreatic cancer is no longer synonymous with a grim prognosis seems gradually more attainable.
